Aprocitentan
Resistant Hypertension
ApprovedLaunch Phase
Key Facts
About Johnson & Johnson
Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.
View full company profileTherapeutic Areas
Other Resistant Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | CE Mark |
| Firibastat (QGC001) | Quantum Genomics | Phase 3 |
| DirectAblate Renal Denervation System | Symple Surgical | Pre-clinical |
| Baxdrostat | AstraZeneca | Phase III |
| TRYVIO/JERAYGO (aprocitentan) | Idorsia | Marketed |